Breaking News

AstraZeneca Pledges $287M to Increase Presence in UK

Plans include a new R&D facility and the expansion of its vaccine manufacturing capabilities.

Author Image

By: Charlie Sternberg

Associate Editor

AstraZeneca has pledged approximately $827 million to increase its presence in the U.K., including a new R&D facility in Liverpool and the expansion of its vaccine manufacturing capabilities, BioSpace reports. New Facility in Liverpool Approximately $573 million of AstraZeneca’s commitment will be used to construct a new facility for the research, development and manufacture of vaccines in Speke, Liverpool. The new campus, which will be designed to be operationally net zero and draw pow...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters